The present invention relates generally to the fields of molecular biology andgrowth factor regulation.More specifically, the invention relates to therapies for the treatment ofpathological conditions, such ascancer. Even more specifically, the invention relates to compositionscomprising cobimetinib andvemurafenib and their use in the treatment of BRAF-V600 mutation-positiveunresectable or metastaticmelanoma.